Wednesday, July 22, 2009

Bristol-Myers Squibb to Acquire Medarex

I believe, BMS now has the the Monopoly on Anti-CTLA-4 monoclonal antibodies. BMS wants it all. Greed at its finest.

"What sets us(BMS) apart?" Greed!!!!!!!!

And what does Bristol-Myers Squibb say:

"What sets us apart? We believe it's our commitment to patients with serious diseases, our focus on finding innovative medicines that combat those diseases, and our dedication to extending and enhancing human life.”

This is nice PR, but if you don’t walk the walk and it is all talk, then it means NOTHING!!!!!!!


Positions Bristol-Myers Squibb for Long-Term Leadership in Biologics Acquires Proven Antibody Discovery Technology Gains Full Rights to Promising Phase III Compound, Ipilimumab Significantly Expands Oncology and Immunology Pipeline

Bristol-Myers Squibb Company (NYSE:BMY) and Medarex, Inc. (NASDAQ: MEDX) announced
today that the companies have signed a definitive merger agreement
providing for the acquisition of Medarex by Bristol-Myers Squibb, for
$16.00 per share in cash. The transaction, with an aggregate purchase
price of approximately $2.4 billion, has been unanimously approved by
the boards of directors of both companies. Medarex's projected $300
million in net cash and marketable securities at closing would be an
asset acquired by Bristol-Myers Squibb resulting in an implied purchase
price of approximately $2.1 billion.

The Board must have deep pockets!!!!!!!!!!!!!!!! What is their cut??

"Medarex's technology platform, people and pipeline provide a strong
complement to our company's biologics strategy, specifically in
immuno-oncology," said James
M. Cornelius, chairman and chief executive officer, Bristol-Myers
Squibb. "With its productive and proven antibody discovery capabilities,
ability to generate interesting therapeutic programs and unique set of
pre-clinical and clinical assets in development, Medarex represents what
we're looking for in terms of our String
of Pearls strategy. This acquisition is another important step in
our BioPharma transformation."

"We believe that this combination with Bristol-Myers Squibb, a global
leader in oncology, provides an excellent opportunity to realize the
full potential of Medarex's development portfolio and our UltiMAb(R)
technology platform through a transaction which also provides an
attractive valuation for our shareholders," said Howard H. Pien,
chairman and chief executive officer, Medarex. "Medarex has evolved
significantly over the past two decades from a research platform to a
development company. We believe that this transaction represents a great
opportunity to place our clinical programs and technology assets in the
hands of one of the world's premier biopharmaceutical companies with the
expertise, resources, motivation and dedication to bring innovative
cancer treatment options to patients in need."

Bristol-Myers Squibb gains the following as a result of the acquisition:

Medarex's UltiMAb Human Antibody Development System(R), which produces
high affinity, fully human antibodies for use in a broad range of
therapeutic areas, including immunology and oncology. This validated
technology platform has produced compounds which are now currently
marketed therapies (SIMPONI(TM), STELARA(TM) and ILARIS(R)).

Medarex's next-generation Antibody-Drug Conjugate (ADC) technology,
which is a novel and proprietary platform that could open new fields
in oncology drug development.

Rights to seven antibodies in clinical trials under Medarex's sole
sponsorship and three other antibodies being co-developed with other
partners. Rights to pre-clinical assets in various stages of
development by Medarex -- in particular, monoclonal antibodies focused
in oncology and immunology.

Full ownership and rights to ipilimumab, which, if approved, could be
an important contributor to Bristol-Myers Squibb's future growth. The
companies have collaborated on the development of ipilimumab, a novel
immunotherapy currently in Phase III development for the treatment of
metastatic melanoma. The companies also have an ongoing Phase II study
in lung cancer as well as Phase III studies in adjuvant melanoma and
hormone-refractory prostate cancer.

Royalties based on percentage of sales for SIMPONI(TM), STELARA(TM) and

"We welcome the opportunity to further collaborate with the Medarex
scientific leadership," said Elliott Sigal, M.D., Ph.D., executive vice
president and president, research and development at Bristol-Myers
Squibb. "In addition to our Adnexus team, which has been expanded since
it was acquired in 2007, Medarex scientists will help us create an
industry-leading biologics capability. We believe Medarex's antibody
generation expertise, located in California and New Jersey, will
complement our existing biologics efforts with a dedicated discovery and
development capability in immuno-oncology."

Under the terms of the definitive merger agreement, Bristol-Myers Squibb
will commence a cash tender offer on or about July 27, 2009 to purchase
all of the outstanding shares of Medarex common stock for $16.00 per
share in cash. The closing of the tender offer is subject to customary
terms and conditions, including the tender of a number of shares that,
together with the number of shares already owned by Bristol-Myers
Squibb, constitutes at least a majority of Medarex's outstanding shares
of common stock (on a fully diluted basis) and expiration or termination
of the waiting period under the Hart Scott Rodino Antitrust Improvement
Act. The agreement also provides for the parties to effect, subject to
customary conditions, a merger to be completed following the completion
of the tender offer which would result in all shares not tendered in the
tender offer being converted into the right to received $16.00 per share
in cash. The merger agreement contains a provision under which Medarex
has agreed not to solicit any competing offers for the company.
Bristol-Myers Squibb will finance the acquisition from its existing cash
resources. The companies expect the tender offer to close in
approximately thirty (30) days after commencement of the tender offer.

JPMorgan Securities, Inc. is serving as financial advisor to
Bristol-Myers Squibb in connection with the acquisition, and
Bristol-Myers Squibb is represented by Cravath, Swaine & Moore LLP, New
York, New York. Goldman, Sachs & Co. is serving as financial advisor to
Medarex in connection with the acquisition, and Medarex is represented
by Covington & Burling LLP, New York, New York.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to extend and enhance human life. For more information visit

Take Care,

Jimmy B

No comments:

Post a Comment

Greetings to One and All

This Blog is dedicated My Brother Kenny B. who passed away in the late 1970's with Cancer before the Internet.

It was he, who showed me How to live and give back. He was wise beyond his years.

Kenny B

Jimmy and Dee

Carepage: Jimmybreitfeller
Jimmy Breitfeller

My Profile as of 2009

My photo
Last July (2005)I was riding my bicycle to work at the Eastman Kodak Research Labs about 3 miles from home. I was wearing a knapsack to carry my things to and from the labs. I started noticing an ache on my back. So I decide to go to the dermatologist. To make the long story short, it was cancer. I knew from my research that I would be needing adjuvant therapy. So I started communicating with Sloan Kettering, University of Pittsburgh Cancer Center, and a couple of others including the Wilmot Cancer Center at Strong. I realized that by telling my story, I might help someone else out there in a similar situation. So to all who are linked by diagnosis or by relation to someone with melanoma, I wish you well. Stay positive, read as much as you can (information helps to eliminate the fear associated with the unknown), and live for today, as no one can predict what tomorrow may bring. Jimmy B. posted 12/15/08


The information contained within this Blog is not meant to replace the examination or advice of your Oncologist or Medical Team. The educational material that is covered here or Linked to, does not cover every detail of each disorder discussed.

Only your physician/Oncologist can make medical decisions and treatment plans that are appropriate for you. But, An Educated Consumer is a Smart consumer.

As Dr. Casey Culberson Said:

"The BEST melanoma patient is an ACTIVE PARTICIPANT in his or her treatment

Melanoma and the “Magic Bullet” (Monoclonal Antibodies)

Just to let you know I posted the first draft of the Melanoma and the “Magic Bullet” (Monoclonal Antibodies). on Melanoma Missionary In the Shared File Section. you can download it for 19.95 (Only kidding) it is Free for the taking.

It is 33 pages long and may help you in your quest for the Yellow Brick Broad. Just to let you know it is only the first draft. Revisions are sure to come. I wanted to get it to the people that need it the most, the Melanoma Patients.


So, where does Interluekin-2 (IL-2) come into play? According to Byung-Scok et al and recent reports, IL-2 is not needed for developmental CD4+ CD25+ Treg cells in the thymus but does play an important role in the maintenance and function in the peripheral.18 Peripheral is defines as secondary system outside the bone marrow and thymus. It entails the site of antigen, immune system interaction. IL-2 is required for the peripheral generation of Tregs based Abbas’s and colleagues research.19

IL-2 prevents the spontaneous apoptosis of the CD4+ CD25+ Treg cells. It has been reported that patients with multiple advance-stage tumors have elevated levels of Tregs within the tumor microenviroment.20 Interluekin-2 is the survival factor for CD4+ CD25+ Treg cells.21 If the addition of IL-2 is on or before the maximum propagation of the CD4+ T cells, the Tregs population can increase 5-fold in a 96 hour period based on certain growth mediums.

By controlling the addition of the endogenous IL-2, one has a knob to turn and can lead to the control of the expansion of the Tregs. When you combined this control with the anti-CTLA-4 blockage, you can shift the balance of the immune response.

Now here is the catch. The maintenance and function of the CD8+ T-cells require CD4+ cells which secrete IL-2. So we don’t want to deplete the CD4+ cells, we want to control the expansion of the Tregs which are a subset of the CD4+ cells. It has been postulated by some researchers that the Anti-CTLA-4 blockage also suppresses the Treg function in a different mechanism. By using IL-2 as the rate limiting factor, we can suppress the CD4+ CD25+ Treg cell expansion by controlling the concentration and timing of the Inerluekin-2 at the tumor microenvironment.

The Interluekin-2 plays another role in this Melanoma Maze. In a study by Janas et al, Il-2 increases the expressions of the perforin and granzyme A, B and C genes in the CD8+ T-cells. This increase expression causes the CD8+ T-cells to mature into Cytoxic T Lymphocytes (CTLs). The exogenous IL-2 is required for the granzyme proteins. As stated previously, CTLs have cytoplasmic granules that contain the proteins perforin and granzymes. A dozen or more perforin molecules insert themselves into the plasma membrane of target cells forming a pore that enables granzymes to enter the cell. Once in the tumor cell, these enzymes are able to breakup (lyse) the cell and destroy it. This is the beginning of the end for the cancer cells. The tumors begin to shrink and the rest is history,

On the other hand, prolong therapy with Il-2 can result in causing apoptotic death of the tumor- specific CD8+ T-cells.23

Clearly in a clinical setting, timing, dose, and exposure to these drugs play a major roll in the immunotherapy, and can have dramatic effects on the outcome.

All it takes is that one magic bullet to start the immune reaction..

Melanoma And The Magic Bullet (Monoclonal Antibodies)

Public Service Announcement

A call for Melanoma Patients by Dr. Steven A Rosenberg

"We continue to see a high rate of clinical responses in our cell transfer immunotherapy treatments for patients with metastatic melanoma", Dr. Rosenberg said.

"We are actively seeking patients for these trials and any note of that on a patient-directed web site would be appreciated."

If you would like to apply for his trials, here is the website and information.

Dr. Rosenberg's information

Dr. Rosenberg's Clinical Trials

For the Warriors

The Melanoma Research Alliance has partnered with Bruce Springsteen, the E Street Band, and the Federici family to alleviate suffering and death from melanoma. Please view Bruce Springsteen’s public service announcement inspired by Danny Federici. Danny was the E Street Band’s organist and keyboard player. He died on April 17, 2008 at Memorial Sloan-Kettering Cancer Center in New York City after a three year battle with melanoma.

Source Fastcures blog

Join the Relay for Life!!!


Dear Family and Friends,

I’ve decided to take a stand and fight back against cancer by participating in the American Cancer Society Relay For Life® event right here in my community! Please support me in this important cause by making a secure, tax-deductible donation online using the link below.

To donate on line now, click here to visit my personal page.
Jimmy B AKA Melanoma_Missionary

Relay For Life® is a life-changing event that brings together more than 3.5 million people worldwide to:

CELEBRATE the lives of those who have battled cancer. The strength of survivors inspires others to continue to fight.

REMEMBER loved ones lost to the disease. At Relay, people who have walked alongside people battling cancer can grieve and find healing.

FIGHT BACK. We Relay because we have been touched by cancer and desperately want to put an end to the disease.

Whatever you can give will help - it all adds up! I greatly appreciate your support and will keep you posted on my progress.

Keep the Fire Burning!!!



Jimmy Breitfeller
Turn off Music before you "Click to Play"
Signs of Melanoma Carcinoma Skin Cancer

How Skin Cancer Develops by " : Dermatology"

Call for Patients with Unresectable Liver Metastases Due to Melanoma

Delcath Systems Granted Orphan-Drug Designations for Cutaneous and Ocular Melanoma

Delcath is actively enrolling patients in a Phase III clinical trial testing its proprietary drug delivery system, known as Percutaneous Hepatic Perfusion (“PHP”), with melphalan for the treatment of ocular and cutaneous melanoma metastatic to the liver.

This NCI-led trial is enrolling patients at leading cancer centers throughout the United States. Commenting on these orphan-drug designations, Richard L. Taney, President and CEO of Delcath, stated, “These favorable designations are important steps in our efforts to secure Delcath’s commercial position upon conclusion of our pivotal Phase III trial for metastatic melanoma. We remain steadfast in our commitment to become the leader in the regional treatment of liver cancers and we continue to enroll patients in this study, and advance our technology and the promise that it offers to patients with these deadly forms of melanoma and other cancers of the liver, all with limited treatment options.”

Orphan drug designation, when granted by the FDA’s Office of Orphan Products Development, allows for up to seven years of market exclusivity upon FDA approval, as well as clinical study incentives, study design assistance, waivers of certain FDA user fees, and potential tax credits.

Current Trial Centers

Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using
Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies

James F. Pingpank, Jr., MD, FACS
Associate Professor of Surgery
Division of Surgical Oncology
Suite 406, UPMC Cancer Pavillion
5150 Centre Avenue
Pittsburgh, PA 15232
412-692-2852 (Office)
412-692-2520 (Fax)

Blog Archive

Call For Melanoma Patients!!!!

Call For Melanoma Patients!!!!

Dr. Rosenberg Has a New Clinical Trial.

Our latest treatment has a 72% objective response rate with 36% complete responses.

We are currently recruiting patients for our latest trial.

Is there some way to post this “Call for Patients” on the web site?

Steve Rosenberg

Dr. Rosenberg's Clinical Trials

(For a copy of the research paper.. see My Shared files)

The news headlines shown above for Melanoma / Skin Cancer are provided courtesy of Medical News Today.